A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival-Reference-Cited by-同舟云学术

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

Published:2016-12 Issue:6 Volume:43 Page:682-689
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Kazandjian Dickran,Landgren Ola

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference50 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient;Landgren;Cytometry Clin Cytometry,2016

3. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis;Landgren;Bone Marrow Transplant,2016

4. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis;Munshi;JAMA Oncol,2016

5. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e346.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence, outcomes, and complications of vitamin D deficiency among patients with multiple myeloma: Nationwide burden of disease;Journal of Investigative Medicine;2024-06-16

2. Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis;Haematologica;2023-10-26

3. Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis;European Journal of Haematology;2023-08-13

4. Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA;Future Oncology;2023-07

5. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL);American Journal of Hematology;2023-06-19